SCOPUS 정보 검색 플랫폼

Volumn 59, Issue 3, 2015, Pages 1441-1445

Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections

(7) Bhansali, Suraj G a Mullane, Kathleen b Ting, Lillian S L a Leeds, Jennifer A c Dabovic, Kristina d Praestgaard, Jens a Pertel, Peter d

a NOVARTIS PHARMA AG (Switzerland)

b UNIVERSITY OF CHICAGO MEDICAL CENTER (United States)

c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (United States)

d NONE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LFF 571; VANCOMYCIN; ANTIINFECTIVE AGENT; THIAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FECES LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; CHEMISTRY; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; FECES; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; THIAZOLES; VANCOMYCIN;

EID: 84923255561 PISSN: 00664804 EISSN: 10986596 Source Type: Journal
DOI: 10.1128/AAC.04252-14 Document Type: Article

Times cited : (30)

References (21)

1
- 77951026738
- Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
- (2010) Infect Control Hosp Epidemiol , vol.31 , pp. 431-455
- Cohen, S.H.¹ Gerding, D.N.² Johnson, S.³ Kelly, C.P.⁴ Loo, V.G.⁵ McDonald, L.C.⁶ Pepin, J.⁷ Wilcox, M.H.⁸

2
- 28844441314
- A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality
- Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. 2005. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353:2442-2449. http://dx.doi.org/10.1056/NEJMoa051639.
- (2005) N Engl J Med , vol.353 , pp. 2442-2449
- Loo, V.G.¹ Poirier, L.² Miller, M.A.³ Oughton, M.⁴ Libman, M.D.⁵ Michaud, S.⁶ Bourgault, A.M.⁷ Nguyen, T.⁸ Frenette, C.⁹ Kelly, M.¹⁰ Vibien, A.¹¹ Brassard, P.¹² Fenn, S.¹³ Dewar, K.¹⁴ Hudson, T.J.¹⁵ Horn, R.¹⁶ Rene, P.¹⁷ Monczak, Y.¹⁸ Dascal, A.¹⁹

3
- 28844494086
- An epidemic, toxin genevariant strain of Clostridium difficile
- McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 353:2433-2441. http://dx.doi.org/10.1056/NEJMoa051590.
- (2005) N Engl J Med , vol.353 , pp. 2433-2441
- McDonald, L.C.¹ Killgore, G.E.² Thompson, A.³ Owens, R.C.⁴ Kazakova, S.V.⁵ Sambol, S.P.⁶ Johnson, S.⁷ Gerding, D.N.⁸

4
- 79551527297
- Fidaxomicin versus vancomycin for Clostridium difficile infection
- Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
- (2011) N Engl J Med , vol.364 , pp. 422-431
- Louie, T.J.¹ Miller, M.A.² Mullane, K.M.³ Weiss, K.⁴ Lentnek, A.⁵ Golan, Y.⁶ Gorbach, S.⁷ Sears, P.⁸ Shue, Y.K.⁹

5
- 84859007390
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial
- Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281-289. http://dx.doi.org/10.1016/S1473-3099(11)70374-7.
- (2012) Lancet Infect Dis , vol.12 , pp. 281-289
- Cornely, O.A.¹ Crook, D.W.² Esposito, R.³ Poirier, A.⁴ Somero, M.S.⁵ Weiss, K.⁶ Sears, P.⁷ Gorbach, S.⁸

6
- 84863288432
- Discovery of LFF571: An investigational agent for Clostridium difficile infection
- LaMarche MJ, Leeds JA, Amaral A, Brewer JT, Bushell SM, Deng G, Dewhurst JM, Ding J, Dzink-Fox J, Gamber G, Jain A, Lee K, Lee L, Lister T, McKenney D, Mullin S, Osborne C, Palestrant D, Patane MA, Rann EM, Sachdeva M, Shao J, Tiamfook S, Trzasko A, Whitehead L, Yifru A, Yu D, Yan W, Zhu Q. 2012. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J Med Chem 55:2376-2387. http://dx.doi.org/10.1021/jm201685h.
- (2012) J Med Chem , vol.55 , pp. 2376-2387
- Lamarche, M.J.¹ Leeds, J.A.² Amaral, A.³ Brewer, J.T.⁴ Bushell, S.M.⁵ Deng, G.⁶ Dewhurst, J.M.⁷ Ding, J.⁸ Dzink-Fox, J.⁹ Gamber, G.¹⁰ Jain, A.¹¹ Lee, K.¹² Lee, L.¹³ Lister, T.¹⁴ McKenney, D.¹⁵ Mullin, S.¹⁶ Osborne, C.¹⁷ Palestrant, D.¹⁸ Patane, M.A.¹⁹ Rann, E.M.²⁰ more..

7
- 84860186057
- Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria
- Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 56:2493-2503. http://dx.doi.org/10.1128/AAC.06305-11.
- (2012) Antimicrob Agents Chemother , vol.56 , pp. 2493-2503
- Citron, D.M.¹ Tyrrell, K.L.² Merriam, C.V.³ Goldstein, E.J.⁴

8
- 84882403677
- Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: Clinical and therapeutic implications
- Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ, ECDIS Study Group. 2013. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications. J Antimicrob Chemother 68:1305-1311. http://dx.doi.org/10.1093/jac/dkt013.
- (2013) J Antimicrob Chemother , vol.68 , pp. 1305-1311
- Debast, S.B.¹ Bauer, M.P.² Sanders, I.M.³ Wilcox, M.H.⁴ Kuijper, E.J.⁵

9
- 84864386615
- Efficacy of LFF571 in a hamster model of Clostridium difficile infection
- Trzasko A, Leeds JA, Praestgaard J, Lamarche MJ, McKenney D. 2012. Efficacy of LFF571 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 56:4459-4462. http://dx.doi.org/10.1128/AAC.06355-11.
- (2012) Antimicrob Agents Chemother , vol.56 , pp. 4459-4462
- Trzasko, A.¹ Leeds, J.A.² Praestgaard, J.³ Lamarche, M.J.⁴ McKenney, D.⁵

10
- 84868024327
- A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers
- Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P. 2012. A first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob Agents Chemother 56:5946-5951. http://dx.doi.org/10.1128/AAC.00867-12.
- (2012) Antimicrob Agents Chemother , vol.56 , pp. 5946-5951
- Ting, L.S.¹ Praestgaard, J.² Grunenberg, N.³ Yang, J.C.⁴ Leeds, J.A.⁵ Pertel, P.⁶

11
- 84923252565
- Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections
- Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P. 2015. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother 59: 1435-1440. http://dx.doi.org/10.1128/AAC.04251-14.
- (2015) Antimicrob Agents Chemother , vol.59 , pp. 1435-1440
- Mullane, K.¹ Lee, C.² Bressler, A.³ Buitrago, M.⁴ Weiss, K.⁵ Dabovic, K.⁶ Praestgaard, J.⁷ Leeds, J.A.⁸ Blais, J.⁹ Pertel, P.¹⁰

12
- 85081860936
- abstr P-1440. Abstracts of the 22nd European Society of Clinical Microbiology and Infectious Diseases, 31 March to 3 April 2012, London, United Kingdom
- Hecht D, Osmolski JR, Gerding D. 2012. In vitro activity of LFF571 against 103 clinical isolates of Clostridium difficile, abstr P-1440. Abstracts of the 22nd European Society of Clinical Microbiology and Infectious Diseases, 31 March to 3 April 2012, London, United Kingdom.
- (2012) Vitro Activity of LFF571 Against 103 Clinical Isolates of Clostridium Difficile
- Hecht, D.¹ Osmolski, J.R.² Gerding, D.³

13
- 84863710720
- Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection
- Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. 2012. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S116-S120. http://dx.doi.org/10.1093/cid/cis337.
- (2012) Clin Infect Dis , vol.55 , pp. S116-S120
- Sears, P.¹ Crook, D.W.² Louie, T.J.³ Miller, M.A.⁴ Weiss, K.⁵

14
- 42049099454
- Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses
- Shue YK, Sears PS, Shangle S, Walsh RB, Lee C, Gorbach SL, Okumu F, Preston RA. 2008. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 52:1391-1395. http://dx.doi.org/10.1128/AAC.01045-07.
- (2008) Antimicrob Agents Chemother , vol.52 , pp. 1391-1395
- Shue, Y.K.¹ Sears, P.S.² Shangle, S.³ Walsh, R.B.⁴ Lee, C.⁵ Gorbach, S.L.⁶ Okumu, F.⁷ Preston, R.A.⁸

15
- 79960391202
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
- Babakhani F, Gomez A, Robert N, Sears P. 2011. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 60:1213-1217. http://dx.doi.org/10.1099/jmm.0.029470-0.
- (2011) J Med Microbiol , vol.60 , pp. 1213-1217
- Babakhani, F.¹ Gomez, A.² Robert, N.³ Sears, P.⁴

16
- 0018104816
- Oral vancomycin for antibiotic-associated pseudomembranous colitis
- Tedesco F, Markham R, Gurwith M, Christie D, Bartlett JG. 1978. Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet ii:226-228.
- (1978) Lancet , vol.II , pp. 226-228
- Tedesco, F.¹ Markham, R.² Gurwith, M.³ Christie, D.⁴ Bartlett, J.G.⁵

17
- 0021152610
- Absorption of vancomycin
- Dudley MN, Quintiliani R, Nightingale CH, Gontarz N. 1984. Absorption of vancomycin. Ann Intern Med 101:144. http://dx.doi.org/10.7326/0003-4819-101-1-144-1.
- (1984) Ann Intern Med , vol.101 , pp. 144
- Dudley, M.N.¹ Quintiliani, R.² Nightingale, C.H.³ Gontarz, N.⁴

18
- 79954467511
- Systemic absorption of oral vancomycin in patients with Clostridium difficile infection
- Rao S, Kupfer Y, Pagala M, Chapnick E, Tessler S. 2011. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand J Infect Dis 43:386-388. http://dx.doi.org/10.3109/00365548.2010.544671.
- (2011) Scand J Infect Dis , vol.43 , pp. 386-388
- Rao, S.¹ Kupfer, Y.² Pagala, M.³ Chapnick, E.⁴ Tessler, S.⁵

19
- 0020955353
- Absorption of oral vancomycin-possible associated toxicity
- Thompson CM, Jr, Long SS, Gilligan PH, Prebis JW. 1983. Absorption of oral vancomycin-possible associated toxicity. Int J Pediatr Nephrol 4:1-4.
- (1983) Int J Pediatr Nephrol , vol.4 , pp. 1-4
- Thompson, C.M.¹ Long, S.S.² Gilligan, P.H.³ Prebis, J.W.⁴

20
- 0021248971
- Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis
- Spitzer PG, Eliopoulos GM. 1984. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med 100: 533-534. http://dx.doi.org/10.7326/0003-4819-100-4-533.
- (1984) Ann Intern Med , vol.100 , pp. 533-534
- Spitzer, P.G.¹ Eliopoulos, G.M.²

21
- 78751560495
- Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis
- Chihara S, Shimizu R, Furukata S, Hoshino K. 2011. Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis. Scand J Infect Dis 43:149-150. http://dx.doi.org/10.3109/00365548.2010.513066
- (2011) Scand J Infect Dis , vol.43 , pp. 149-150
- Chihara, S.¹ Shimizu, R.² Furukata, S.³ Hoshino, K.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.